Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Change in Intangibles (2020 - 2026)

Harvard Bioscience (HBIO) reported Change in Intangibles of $194000.0 for Q1 2026, up 14.12% year-over-year from $170000.0 in Q1 2025, and up 29.33% on a QoQ basis from $150000.0 in Q4 2025.

Harvard Bioscience (HBIO) has 6 years of Change in Intangibles data on file, last reported at $194000.0 in Q1 2026.

  • Quarterly Change in Intangibles rose 14.12% year-over-year to $194000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $629000.0 (down 11.9% YoY) and the FY2025 annual result came in at $605000.0, down 2.26% from the prior year.
  • Change in Intangibles grew to $194000.0 in Q1 2026 per HBIO's latest filing, from $150000.0 in the prior quarter.
  • Across five years, Change in Intangibles topped out at $231000.0 in Q4 2023 and bottomed at $75000.0 in Q1 2024.
  • The 4-year median for Change in Intangibles is $157500.0 (2024), against an average of $161750.0.
  • Peak annual rise in Change in Intangibles reached 126.67% in 2025, while the deepest fall reached 38.96% in 2025.
  • Tracing HBIO's Change in Intangibles over 4 years: stood at $231000.0 in 2023, then dropped by 28.57% to $165000.0 in 2024, then retreated by 9.09% to $150000.0 in 2025, then rose by 29.33% to $194000.0 in 2026.
  • Per Business Quant, the three latest HBIO Change in Intangibles figures stand at $194000.0 (Q1 2026), $150000.0 (Q4 2025), and $141000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Intangibles (Qtr)
1 Intuitive Surgical 156.17 Bn 151.78 Bn 1.83 Bn -
2 Becton Dickinson 41.51 Bn 40.49 Bn 2.15 Bn -
3 Resmed 30.43 Bn 28.77 Bn 890.98 Mn -
4 West Pharmaceutical Services 22.78 Bn 22.26 Bn 296.40 Mn -
5 Solventum 13.39 Bn 13.39 Bn 1.10 Bn -
6 Cooper Companies 12.33 Bn 12.20 Bn 695.20 Mn -
7 Align Technology 11.65 Bn 10.59 Bn 736.59 Mn -
8 Baxter International 9.81 Bn 7.77 Bn 891.00 Mn -
9 Aptargroup 7.39 Bn 7.19 Bn 351.91 Mn 592,000.00
10 Harvard Bioscience 25.38 Mn 18.29 Mn 12.24 Mn 194,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 194,000.00
Mar 31, 2026 194,000.00
Dec 31, 2025 150,000.00
Dec 31, 2025 150,000.00
Sep 30, 2025 141,000.00
Sep 30, 2025 141,000.00
Jun 30, 2025 144,000.00
Jun 30, 2025 144,000.00
Mar 31, 2025 170,000.00
Mar 31, 2025 170,000.00
Dec 31, 2024 165,000.00
Dec 31, 2024 165,000.00
Sep 30, 2024 231,000.00
Sep 30, 2024 231,000.00
Jun 30, 2024 148,000.00
Jun 30, 2024 148,000.00
Mar 31, 2024 75,000.00
Mar 31, 2024 75,000.00
Dec 31, 2023 231,000.00
Dec 31, 2023 231,000.00
Sep 30, 2023 184,000.00
Sep 30, 2023 184,000.00
Jun 30, 2023 108,000.00
Jun 30, 2023 108,000.00
Mar 31, 2021 150,000.00
Mar 31, 2021 150,000.00
Dec 31, 2020 250,000.00
Dec 31, 2020 250,000.00